| Objective:To investigate the expression of mi R-155 and SHIP1, AKT m RN A in the bone marrow mononuclear cells(BMMCs) of acute myeloid leukemia(AML) patients, and analyze the clinical significance of mi R-155 and SHIP1, AKT in patients with AML, and explore preliminarily the role of mi R-155 and PI3K/AKT signaling pathway in the pathogenesis of AML, providing theoretical basis for the target treatment of mi R-155. Methods:1. Total 80 cases of bone marrow samples were collected from AML pa tients, of which included 46 cases of new diagnosed patients, 34 cases of patients in complete remission; The control group in 11 cases, for patients with iron deficiency anemia.2. Real- time fluorescent quantitative PC R method is used to detect respective ly the expression level of mi R-155, U6 and SHIP1, AKT, GAPDH m RN A in bone marrow samples from AML patients. The relative quantification method was used to calculate the relative expression levels of mi R-155 and SHIP1, AKT m RNA, the formula 2- Δ Ct ×102was used to calculate relative gene expression values.3. SPSS17.0 statistical software was used to analyze the experimental data. Measurement data are non-normal distribution, were described by the median, using Mann-Whitney U test, Spearman correlation test was used to analyze the correlation; the chi-square test was used for count data. P value < 0.05 was considered statistically significant. Results:1. The relative expression of mi R-155 in bone marrow mononuclear cell from AML patients of the new diagnosed group 4.2931(2.1642 ~ 8.8388) and the remission group 3.6853(2.3697 ~ 5.2406) were significantly higher than the control group 2.5190(0.9848 ~ 4.9360), P values were respectively 0.001 and 0.004, the differences were statistically significant(P <0.01); the expression level of mi R-155 of the new diagnosed group was also significantly higher than the remission group, the differences were statistically significant(P = 0.022).2. The relative expression of mi R-155 in bone marrow mononuclear cell from AML patients of the moderate prognosis group 4.3587(2.3519 ~ 8.8388) and the poor group 5.8910(3.2193 ~ 7.9801) were significantly higher than the favorable group 3.4706(2.1642 ~ 5.2193), P values were respectively 0.036 and 0.022, the differences were statistically significant(P <0.05); the middle group and the poor group showed no statistical difference(P = 0.174).3. According to the median expression level of mi R-155, the 34 cases new diagnosed patients were divided into the high expression group( mi R-155 expression ≥3.9656) and the low expression group(mi R-155 expression <3.9656), showed that the initial induction remission rate of the high expression group and the low expression group were 88.9% and 56.3%, and the difference was statistically significant(χ2 = 4.636, P =0.031); And the expressions levels of mi R-155 in new diagnosed of patients without complete remission after chemotherapy5.3700(2.9360 ~ 8.8388) were significantly higher than those patients with complete remission after chemotherapy 3.9012(2.1642 ~ 7.9801), the difference was statistically significant(P = 0.005).4. In new diagnosed group, the relative expression level of mi R-155 showed no significantly correlation with patient’s age and the proportion of blast cells in bone marrow, the peripheral blood leukocyte count, the peripheral blood hemoglobin count, the peripheral blood platelet count(P> 0.05).5. The relative expression level of SHIP1 m RNA in bone marrow mononuclear cell from AML patients of the new diagnosed group was 0.9083(0.0137 ~ 2.8756), the remission group was 1.8597(0.6848 ~ 4.2986), the control group was 1.9740(0.3696 ~ 4.4502); the remission group and the control group were significantly higher than the new diagnosed group, P values were respectively 0.002 and 0.005, the differences were statistically significant(P <0.01); the remission group and the control group showed no statistical difference(P = 0.174).6. The relative expression of AKT m RNA in bone marrow mononuclear cells from AML patients in new diagnosed group was 4.5486(2.1105 ~ 8.2922), the remission group was 4.1122(1.6328 ~ 8.0067), the control group was 4.2691(1.7854 ~ 6.4944), the difference between any two groups showed no statistical difference(P> 0.05).7. In new diagnosed group, the relative expression levels of mi R-155 and SHIP1 m RNA showed negative correlation(r =-0.354, p = 0.016), the relative expression levels of SHIP1 and AKT m RNA were also negatively correlated(r =-0.398, p = 0.006); in remission group, the relative expression levels of mi R-155 and SHIP1 m RNA showed positive correlation(r = 0.590, p = 0.001), the relative expression levels of SHIP1 and AKT m RNA showed no significant correlation(r =-0.216, p = 0.270); in the control group, the relative expression levels of mi R-155 and SHIP1 m RNA showed no significant correlation(r =-0.145, p = 0.670), the relative expression levels of SHIP1 and AKT m RNA showed positive correlation(r = 0.609, p = 0.047). Conclusion:1. mi R-155 was highly expressed in bone marrow mononuclear cells of AML patients, its expression level was associated with disease states.2. The expression level of mi R-155 was associated with the prognosis of AML, the moderate group and the poor group were significantly higher than the favorable group. the expression level of mi R-155 was associated with the clinical effect of AML, the remission rate of patients with mi R-155 high expression is lower.3. mi R-155 and the proportion of bone marrow blasts, peripheral blood leukocyte, hemoglobin and platelet count and age showed no significant correlation.4. SHIP1 m RN A in bone marrow mononuclear cells of AML patients showed lower expression. the expression levels of AKT m RNA in bone marrow mononuclear cel s of AML patients showed no significant change.5. In new diagnosed group, the relative expression levels of mi R-155, SHIP1 m RNA and SHIP1, AKT m RNA showed negative correlation. |
PDF Full Text Request